Predicting seizures in pregnant women with epilepsy: Development and external validation of a prognostic model

• Published in: PLoS medicine Vol. 16; no. 5; p. e1002802
• Main Authors: Allotey, John, Fernandez-Felix, Borja M, Zamora, Javier, Moss, Ngawai, Bagary, Manny, Kelso, Andrew, Khan, Rehan, van der Post, Joris A M, Mol, Ben W, Pirie, Alexander M, McCorry, Dougall, Khan, Khalid S, Thangaratinam, Shakila
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 13.05.2019; Public Library of Science (PLoS)
• Subjects: Adolescent; Adult; Anticonvulsants; Anticonvulsants - therapeutic use; Antiepileptic agents; Brain - drug effects; Brain - physiopathology; Brain Waves - drug effects; Calibration; Care and treatment; Causes of; Child; Classification; Convulsions & seizures; Death; Decision making; Decision Support Techniques; Dentistry; Drugs; Epidemiology; Epilepsy; Epilepsy - diagnosis; Epilepsy - drug therapy; Epilepsy - physiopathology; Etiracetam; Female; Gynecology; Health aspects; Hospital admission and discharge; Hospitals; Humans; Lamotrigine; Levetiracetam; Maternal Health; Maternal mortality; Medicine; Medicine and Health Sciences; Mental disorders; Neurology; Nomograms; Nomographs; Obstetrics; Patient outcomes; Physical Sciences; Postpartum; Predictive Value of Tests; Pregnancy; Pregnancy Complications - diagnosis; Pregnancy Complications - drug therapy; Pregnancy Complications - physiopathology; Pregnant women; Prognosis; Prospective Studies; Public health; Reproducibility of Results; Research and Analysis Methods; Risk Assessment; Risk Factors; Seizures; Seizures (Medicine); Supervision; Systematic review; Thresholds; Womens health; Young Adult; United Kingdom > UK; England; Spain
• ISSN: 1549-1676; 1549-1277; 1549-1676
• DOI: 10.1371/journal.pmed.1002802

Seizures are the main cause of maternal death in women with epilepsy, but there are no tools for predicting seizures in pregnancy. We set out to develop and validate a prognostic model, using information collected during the antenatal booking visit, to predict seizure risk at any time in pregnancy and until 6 weeks postpartum in women with epilepsy on antiepileptic drugs. We used datasets of a prospective cohort study (EMPiRE) of 527 pregnant women with epilepsy on medication recruited from 50 hospitals in the UK (4 November 2011-17 August 2014). The model development cohort comprised 399 women whose antiepileptic drug doses were adjusted based on clinical features only; the validation cohort comprised 128 women whose drug dose adjustments were informed by serum drug levels. The outcome was epileptic (non-eclamptic) seizure captured using diary records. We fitted the model using LASSO (least absolute shrinkage and selection operator) regression, and reported the performance using C-statistic (scale 0-1, values > 0.5 show discrimination) and calibration slope (scale 0-1, values near 1 show accuracy) with 95% confidence intervals (CIs). We determined the net benefit (a weighted sum of true positive and false positive classifications) of using the model, with various probability thresholds, to aid clinicians in making individualised decisions regarding, for example, referral to tertiary care, frequency and intensity of monitoring, and changes in antiepileptic medication. Seizures occurred in 183 women (46%, 183/399) in the model development cohort and in 57 women (45%, 57/128) in the validation cohort. The model included age at first seizure, baseline seizure classification, history of mental health disorder or learning difficulty, occurrence of tonic-clonic and non-tonic-clonic seizures in the 3 months before pregnancy, previous admission to hospital for seizures during pregnancy, and baseline dose of lamotrigine and levetiracetam. The C-statistic was 0.79 (95% CI 0.75, 0.84). On external validation, the model showed good performance (C-statistic 0.76, 95% CI 0.66, 0.85; calibration slope 0.93, 95% CI 0.44, 1.41) but with imprecise estimates. The EMPiRE model showed the highest net proportional benefit for predicted probability thresholds between 12% and 99%. Limitations of this study include the varied gestational ages of women at recruitment, retrospective patient recall of seizure history, potential variations in seizure classification, the small number of events in the validation cohort, and the clinical utility restricted to decision-making thresholds above 12%. The model findings may not be generalisable to low- and middle-income countries, or when information on all predictors is not available. The EMPiRE model showed good performance in predicting the risk of seizures in pregnant women with epilepsy who are prescribed antiepileptic drugs. Integration of the tool within the antenatal booking visit, deployed as a simple nomogram, can help to optimise care in women with epilepsy.